Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Thiazide-associated hyponatremia in internal medicine patients: analysis of epidemiological and biochemical profiles

J. Klhůfek, T. Šálek

. 2022 ; 134 (5) : 487-493. [pub] 20220415

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018260

OBJECTIVES: Thiazide-associated hyponatremia (TAH) is a clinically important side effect of the therapy with thiazide and thiazide-like diuretics. This study aims to analyze epidemiological, biochemical, and symptomatological profiles (including volume status) of patients admitted with TAH. METHODS: A retrospective hospital record study was performed. Epidemiological and biochemical parameters and symptoms were compared between the thiazide (n = 143) and non-thiazide (n = 282) groups. Patients in the thiazide group were classified as hypo-, normo-, or hypervolemic. Furthermore, the comparison of epidemiological, biochemical, partially pharmacotherapeutical, and symptomatological parameters between the hypovolemic and normovolemic TAH groups was performed. RESULTS: The thiazide group showed lower s-Na (p = 0.008), s-K (p < 0.001), s-Cl (p < 0.001), measured s-osmolality (p = 0.021), and eGFR (p < 0.001); higher s-urea (p < 0.001), s-creatinine (p = 0.023), s-glucose (p < 0.001), u-osmolality (p = 0.012), u-Na (p < 0.001), u-K (p = 0.023), and u-Cl (p < 0.001). Patients using thiazide were older (p < 0.001), more likely to be female (p = 0.011), and with symptoms corresponding more to chronic hyponatremia. Compared to the normovolemic group (n = 93; 65%), the hypovolemic patients (n = 47; 32.9%) showed higher s-urea (p = 0.005), s-creatinine (p = 0.045), and s-UA (p = 0.010); lower eGFR (p = 0.032), u-Na (p = 0.015), u-Cl (p = 0.016), anorexia (p < 0.001), and a higher frequency of furosemide use (p < 0.001). CONCLUSIONS: Thiazide use is a crucial etiological cause of hypotonic hyponatremia among internal medicine inpatients, associated with more severe hyponatremia, but with no difference in the in-hospital mortality. Even in hypo-osmolar conditions of TAH, 32.9% of patients exhibited signs of volume depletion. FE-UA did not differ between the hypovolemic and the normovolemic patients in TAH conditions. Anorexia and the combination of thiazide together with furosemide, rather than thiazide use alone, were risk factors for hypovolemic hyponatremia without affecting FE-UA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018260
003      
CZ-PrNML
005      
20220804134646.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/00325481.2022.2063634 $2 doi
035    __
$a (PubMed)35382687
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Klhůfek, Josef $u Department of Clinical Pharmacy, Tomas Bata Hospital in Zlín, a. s, Zlín, The Czech Republic $1 https://orcid.org/0000000183312525
245    10
$a Thiazide-associated hyponatremia in internal medicine patients: analysis of epidemiological and biochemical profiles / $c J. Klhůfek, T. Šálek
520    9_
$a OBJECTIVES: Thiazide-associated hyponatremia (TAH) is a clinically important side effect of the therapy with thiazide and thiazide-like diuretics. This study aims to analyze epidemiological, biochemical, and symptomatological profiles (including volume status) of patients admitted with TAH. METHODS: A retrospective hospital record study was performed. Epidemiological and biochemical para $a OBJECTIVES Thiazide associated hyponatremia TAH is a clinically important side effect of the therapy with thiazide and thiazide like diuretics This study aims to analyze epidemiological biochemical and symptomatological profiles including volume status of patients admitted with TAH METHODS A retrospective hospital record study was performed Epidemiological and biochemical parameters and $a OBJECTIVES: Thiazide-associated hyponatremia (TAH) is a clinically important side effect of the therapy with thiazide and thiazide-like diuretics. This study aims to analyze epidemiological, biochemical, and symptomatological profiles (including volume status) of patients admitted with TAH. METHODS: A retrospective hospital record study was performed. Epidemiological and biochemical parameters and symptoms were compared between the thiazide (n = 143) and non-thiazide (n = 282) groups. Patients in the thiazide group were classified as hypo-, normo-, or hypervolemic. Furthermore, the comparison of epidemiological, biochemical, partially pharmacotherapeutical, and symptomatological parameters between the hypovolemic and normovolemic TAH groups was performed. RESULTS: The thiazide group showed lower s-Na (p = 0.008), s-K (p < 0.001), s-Cl (p < 0.001), measured s-osmolality (p = 0.021), and eGFR (p < 0.001); higher s-urea (p < 0.001), s-creatinine (p = 0.023), s-glucose (p < 0.001), u-osmolality (p = 0.012), u-Na (p < 0.001), u-K (p = 0.023), and u-Cl (p < 0.001). Patients using thiazide were older (p < 0.001), more likely to be female (p = 0.011), and with symptoms corresponding more to chronic hyponatremia. Compared to the normovolemic group (n = 93; 65%), the hypovolemic patients (n = 47; 32.9%) showed higher s-urea (p = 0.005), s-creatinine (p = 0.045), and s-UA (p = 0.010); lower eGFR (p = 0.032), u-Na (p = 0.015), u-Cl (p = 0.016), anorexia (p < 0.001), and a higher frequency of furosemide use (p < 0.001). CONCLUSIONS: Thiazide use is a crucial etiological cause of hypotonic hyponatremia among internal medicine inpatients, associated with more severe hyponatremia, but with no difference in the in-hospital mortality. Even in hypo-osmolar conditions of TAH, 32.9% of patients exhibited signs of volume depletion. FE-UA did not differ between the hypovolemic and the normovolemic patients in TAH conditions. Anorexia and the combination of thiazide together with furosemide, rather than thiazide use alone, were risk factors for hypovolemic hyponatremia without affecting FE-UA.
650    _2
$a nechutenství $x chemicky indukované $x komplikace $x farmakoterapie $7 D000855
650    _2
$a kreatinin $7 D003404
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a furosemid $7 D005665
650    _2
$a lidé $7 D006801
650    12
$a hyponatremie $x chemicky indukované $x epidemiologie $7 D007010
650    _2
$a hypovolemie $x chemicky indukované $7 D020896
650    _2
$a vnitřní lékařství $7 D007388
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a sodík $7 D012964
650    12
$a thiazidy $x škodlivé účinky $7 D049971
650    _2
$a močovina $7 D014508
655    _2
$a časopisecké články $7 D016428
700    1_
$a Šálek, Tomáš $u Department of Clinical biochemistry and pharmacology, Tomas Bata Hospital in Zlín, a. s, Zlín, The Czech Republic $u Institute of Laboratory Medicine, Medical Faculty, University of Ostrava, Ostrava, The Czech Republic $1 https://orcid.org/0000000283925003 $7 xx0174625
773    0_
$w MED00003867 $t Postgraduate medicine $x 1941-9260 $g Roč. 134, č. 5 (2022), s. 487-493
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35382687 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134640 $b ABA008
999    __
$a ok $b bmc $g 1822045 $s 1169503
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 134 $c 5 $d 487-493 $e 20220415 $i 1941-9260 $m Postgraduate medicine $n Postgrad Med $x MED00003867
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...